How big is the preimplantation genetic testing market?

The global preimplantation genetic testing market size was estimated at USD 852.35 million in 2024 and is expected to reach USD 909.11 million in 2025.

What is the preimplantation genetic testing market growth?

The global preimplantation genetic testing market is expected to grow at a compound annual growth rate of 7.1% from 2025 to 2030, reaching USD 1.28 billion by 2030.

Which segment accounted for the largest preimplantation genetic testing market share?

Aneuploidy screening dominated the preimplantation genetic testing market with a revenue share of 26.0% in 2024 and is projected to grow at the fastest rate over the forecast period. The aneuploidy screening is mostly used to determine embryo quality in IVF.

Who are the key players in preimplantation genetic testing market?

Some key players operating in the preimplantation genetic testing market include Illumina Inc.; Thermo Fisher Scientific, Inc.; Natera, Inc.; Bioarray S.L.; Good Start Genetics, Inc.; Laboratory Corporation of America Holdings; California Pacific Medical Center; Quest Diagnostics Incorporated; Reproductive Health Science Ltd.; CooperSurgical, Inc.; Genea Limited; F. Hoffmann-La Roche AG; and CombiMatrix.

What are the factors driving the preimplantation genetic testing market?

Key factors that are driving the market growth include worldwide increase in number of IVF cycles and integration of preimplantation genetic testing in IVF procedures.